Bromocriptine and cocaine cue reactivity in cocaine-dependent patients

Br J Addict. 1992 Nov;87(11):1537-48. doi: 10.1111/j.1360-0443.1992.tb02661.x.

Abstract

Based on previous reports that bromocriptine, a postsynaptic dopamine agonist, reduced cocaine craving and prevented relapse in cocaine-dependent subjects, effects of the drug were evaluated in 20 cocaine-dependent males in an inpatient drug rehabilitation programme. The subjective and physiologic effects of exposure to both cocaine-associated and neutral stimuli, presented using videotapes, were measured at one-week intervals. Between laboratory sessions subjects received either bromocriptine (1.25 mg bid) or a matched placebo, administered in double-blind fashion. Compared with the neutral videotape, the cocaine videotape elicited both a greater desire to use cocaine and more symptoms associated with cocaine self-administration. These results support an appetitive conditioning model of cocaine effects. Bromocriptine, however, had no effect on the cocaine-cue-associated reactivity, which declined over the 1-week interval in both treatment groups. Methodological differences among studies that have examined the effects of bromocriptine in cocaine-dependent subjects may explain the variable findings observed.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Bromocriptine / pharmacology
  • Bromocriptine / therapeutic use*
  • Cocaine*
  • Depressive Disorder / classification
  • Depressive Disorder / diagnosis
  • Humans
  • Male
  • Personality Assessment
  • Placebo Effect
  • Psychiatric Status Rating Scales
  • Substance Abuse Detection
  • Substance Withdrawal Syndrome
  • Substance-Related Disorders / classification
  • Substance-Related Disorders / diagnosis
  • Substance-Related Disorders / drug therapy*
  • Videotape Recording

Substances

  • Bromocriptine
  • Cocaine